AVOID Reddit Mentions | ChartExchange

My AI Slop Analysis:

ONMD is a healthcare AI data company with a genuinely real product and a balance sheet so fucked it makes your accountant cry — the $11.5M deal announced yesterday is either the lifeline that saves them or vaporware that finishes them off. NOT A BABY. WATCH-ONLY until an SEC filing confirms the cash is actually moving.

\---

Let me tell you what every aggregator will hide inside a "TTM revenue" number designed to make this look less embarrassing: OneMedNet's most recent quarterly revenue — the actual number from the most recent SEC filing, Q1 2026 — was $96,000. Not $1.3 million. Not "strong commercial momentum." Ninety-six thousand dollars in a quarter, from a company trading at a $40.4 million market cap. You are being asked to pay 105 times the annualized run rate of a business whose quarterly revenue wouldn't cover the CEO's salary, and you should be genuinely pissed off that the headline 'TTM' number buries that. The trailing twelve months shows $1.3M because there was a one-time Q4 2025 data delivery spike — almost certainly tied to the Palantir partnership announcement — that briefly inflated the revenue line and has since reverted to nothing. Strip that spike out and the actual business doing actual business today is generating about a hundred grand a quarter, on which they lose money before anyone touches G&A, because gross margins are negative fifty percent. Every dollar of revenue they book costs them a dollar fifty to deliver. The financial statements are not a going concern, they're a slow-motion disaster being dressed up in press release language. Losing money on your cost of revenue is not a 'transitional phase,' it's a business that doesn't work yet.

The cash situation makes that disaster immediate. As of March 31, 2026 — confirmed in the 10-Q filed May 15 — OneMedNet had $233,000 in cash against a quarterly burn rate of $2.4 million. That math resolves to nine fucking days of runway. Not nine months, not two quarters — nine days. The auditors said so plainly: the cash balance is "not adequate to fund its operations through at least twelve months." Nasdaq agreed, sending them a minimum bid price deficiency notice on April 20 because the stock had spent 30 consecutive days under $1.00. They have until October 12 to cure that or face delisting — and at $0.71 today, they need a 41% move held for ten straight business days to get compliant, which means either the business actually starts printing money or someone does a reverse split and watches the remaining shareholders get vaporized.

The reason the company is still alive at all is that they've been using a Yorkville Advisors standby equity purchase agreement as an ongoing dilution machine. The structure is simple and brutal: Yorkville buys shares directly from the company at 97% of market price, then dumps them into the open market to get paid back. On July 1 they signed a fresh $25 million SEPA over 36 months layered on top of whatever was left in the prior facility. The scoreboard since the end of 2023: shares outstanding went from 23.6 million to 57 million — a 141% increase in two and a half years, and that dilution is not stopping. Yorkville is not a partner, it is a creditor who gets paid by pissing on your stake once a quarter. Every advance the company takes to cover payroll shows up as a new slug of shares in the float the next week. If you held this stock for the last two years while believing "the fundamentals will catch up eventually," you now own about 40% of what you thought you owned when you bought it.

Then there's the CEO read, because the jockey situation here is more complicated than 'zero buys, bearish tell' and you should look at it with both eyes open. Aaron Green sold $144,722 worth of stock at $2.23 on October 22, 2025 — right at the Palantir partnership pump peak — and another $73,903 at $1.20 on November 18. He has since bought back $51,708 of shares at $0.54-$0.57 in June 2026. So the CEO's personal trade was: sell near the high, buy back at the floor, net positive on the round trip, currently holding cheap paper. There is nothing illegal about that timing. But a man who ran a $2.23 exit in October and a $1.20 exit in November while his company issued bullish press releases about Palantir is not a man who was pricing in a permanent rerating. Not a great look, but not illegal — he's also a first-timer at public companies with no track record to judge him against, which means the 'sell at $2.23, buy at $0.55' move is either savvy hedging or the kind of thing that gets you immortalized in a footnote about management credibility.

The counterweight — and it's a real one — is that Chairman Jeffrey Yu and major holder Thomas Kosasa have put real cash in. Together they've deployed $2.63 million in open-market purchases at average costs under $1.00 per share. Yu bought $100K on June 16 and another $100K on June 23 at $0.58-$0.63. Kosasa's lifetime cash into this position is $1.6 million across 1.9 million shares purchased, with a current position of over 17 million shares. Neither of these are grants, not synthetic "bonus paid in stock" nonsense, not 10b5-1 pre-plan cover — actual cash, actual market prices, actually their own money on the line. Nobody puts $1.6 million of discretionary cash into a company on the assumption it goes to zero. Both are also first-timers at public companies with no prior history to check, so you can't say whether these guys are serial value-creators or first-time gamblers who got lucky on a trade. The absence of a track record is not a red flag — it's just an absence.

Here is what the company actually does, because it matters for understanding why any of this is plausible rather than just a dying penny stock: OneMedNet runs a federated network of 2,300+ healthcare sites covering 90 million patient journeys and 270 million clinical imaging studies, all de-identified and delivered regulatory-grade through their iRWD platform built on Palantir Foundry. In plain English: they have a giant locked vault of real, cleaned, structured medical imaging data — the kind of data you cannot scrape from the internet, cannot synthetically generate, and that every AI lab building in the medical space desperately needs for model training. The moat is not the software, it's the hospital relationships that took years to build and the pipeline that keeps the data current and compliant. That is genuinely valuable. It is also generating $96,000 a quarter in actual recognized revenue right now, which tells you that "genuinely valuable" and "currently monetized" are not the same fucking thing.
Yesterday (July 28), OneMedNet issued a press release — and notably, no SEC 8-K has been filed as of this morning, which should bother you for a contract bigger than their whole annual revenue. The SEC requires material agreements to be reported; not filing means either they don't think it's material, it's not yet a binding definitive agreement, or they're just slower with the paperwork than with the press release machine. Any of those options is annoying in its own way — announcing an $11.5+ million agreement to supply regulatory-grade multi-modal imaging data for foundational AI model development. Counterparty: not disclosed. Payment structure: not disclosed. Revenue recognition timeline: not disclosed. One sentence that matters: "data delivery immediately," which implies cash should be flowing. If this deal is real and structured as a near-term cash payment, it goes from nine days of runway to two-plus years of runway in one wire transfer. The Chairman's quote in the release — "private data is what we believe will ultimately differentiate one foundational model from another" — reads differently knowing he bought $200,000 worth of stock in June, five to six weeks before his company's biggest deal announcement. That is a long enough gap to be clean under securities law. It is also suggestive.

The market moved on this already, and the move is already substantially over. The stock closed July 28 around $0.70, spiked to $0.91 in after-hours on the announcement, and was already giving it all back by the time you could act on it in New York this morning — sitting at $0.71 by 10 AM with volume surging. That is the exact shape of a gap-and-crap on a 15.4 million share float: momentum traders front-run the spike overnight, the retail crowd chases the premarket print at $0.91, and then those same momentum traders dump into the chasers the moment the market opens. Getting in at $0.71 today is not front-running the catalyst. It's buying exit liquidity for someone who got in at $0.57 yesterday and woke up happy. The $11.5M catalyst already fired. The overnight window closed.

The retail crowd is quiet and uninspiring. No meaningful convergence across Reddit's trading communities, no sustained pile-on, a handful of fresh posts from small subs noting the move after it already happened, mixed with what look like automated scalp-alert bots that fire on any premarket mover above a threshold. This is not a name with a following. Nobody is building a thesis here yet. That could be a future opportunity or a sign that the smart money has looked at nine days of cash and moved on to something less existentially precarious.

Nothing else is dated in the near term. No earnings date scheduled. No clinical trial. No PDUFA. The calendar has two relevant events: October 12 (Nasdaq delisting deadline) and whenever Q2 2026 earnings land and show whether the $3M+ in bookings from June and the $11.5M from yesterday actually converted to cash. Both are weeks away and neither one is actionable today.

The verdict is blunt: TRAP on the fundamentals as they currently stand. WATCH on the single specific catalyst risk that the $11.5M deal actually moves cash and transforms the business. HARD AVOID

.dark-mode .gRPMz0{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .gRPMz0{ color: #333333; background-color: white; border: 2px solid #333333; }AVOIDADVANCED VOCE RECGNTN NEWstock OTC

AVOID
ADVANCED VOCE RECGNTN NEW
stock OTC